When Ania Jastreboff and co-authors published the phase 2 retatrutide trial results in the New England Journal of Medicine on June 26, 2023, the peptide research community's reaction was immediate and unambiguous: these were not incremental numbers. The paper — formally titled "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial" — reported efficacy data that repositioned the entire conversation around what the incretin axis could achieve in a controlled research setting.
The trial enrolled 338 adults with obesity or with overweight plus at least one weight-related comorbidity, randomised across multiple dose cohorts to receive weekly subcutaneous injections over 48 weeks in a double-blind, placebo-controlled design. The headline figure — up to 24.2% mean body weight reduction in the highest-dose cohort — instantly became the benchmark against which every subsequent GLP-1 or incretin-adjacent compound gets compared. That number was not a statistical outlier; it reflected a consistent, dose-dependent signal running across the entire trial population.
For researchers operating in the UAE — whether in a university facility near Dubai Science Park, a privately funded lab in Business Bay, or a research practice in Abu Dhabi — the Jastreboff 2023 paper is foundational reading for any protocol touching the GIP, GLP-1, or glucagon receptor axis. What makes it particularly useful is not just the efficacy headline but the granular reporting of secondary endpoints, titration cohort stratifications, and tolerability data that give serious researchers the mechanistic context to design informed protocols. This article unpacks all of it.
Retatrutide (Eli Lilly internal designation LY3437943) is not a molecule that stumbled into triple agonism. Its pharmacological architecture is deliberate: simultaneous activity at the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. Each receptor engagement contributes a distinct signal layer to the compound's overall research profile. Understanding what each does — and why combining them produces something categorically different from mono- or dual agonism — is where serious protocol design begins.
| Receptor Target | Primary Research Signal (Phase 2 Data) | Agonist Activity Level |
|---|---|---|
| GIP Receptor | Enhanced adipose lipid flux; potentiation of GLP-1 CNS signalling; improved insulin sensitivity in adipose tissue | Full agonist |
| GLP-1 Receptor | Gastric motility modulation; central appetite-related signalling; glucose-dependent insulinotropic effect | Full agonist |
| Glucagon Receptor | Hepatic lipid reduction; increased energy expenditure; upregulated lipolysis; thermogenic signalling | Partial agonist |
The glucagon receptor component is where retatrutide most sharply differentiates itself from tirzepatide, Lilly's approved dual GIP/GLP-1 agonist. In isolation, glucagon receptor agonism raises blood glucose — a signal that appears counterproductive for metabolic research contexts. The critical insight in retatrutide's design is that the GLP-1 component effectively buffers the hyperglycaemic signal from glucagon while preserving its metabolically useful outputs: increased hepatic fat oxidation, elevated energy expenditure, and pronounced lipolytic activity in adipose tissue. The Jastreboff 2023 phase 2 paper reported this combination producing measurable reductions in hepatic fat content as a prespecified secondary endpoint — a finding that distinguishes retatrutide's research profile from all single-target predecessors.
For research teams in the UAE designing experiments around hepatic lipid metabolism, non-alcoholic fatty liver disease (NAFLD) models, or adipose tissue biology, this tri-receptor synergy is not an academic footnote. It is the mechanistic rationale for why research groups at institutions across Dubai, Sharjah, and Abu Dhabi have retatrutide on active procurement lists rather than merely on watchlists. The GIP component also adds a dimension not well-studied in mono-GLP-1 research: direct adipocyte signalling that operates independently of the central nervous system pathways. That creates interesting research questions around peripheral vs. central mechanisms of energy balance that retatrutide uniquely enables investigators to probe.
The Jastreboff 2023 NEJM paper was designed as a multi-cohort dose-ranging trial, not a simple two-arm comparison. That design decision produced a dataset that is unusually informative for research purposes because it maps the dose-response relationship across a wide exposure range rather than just confirming that "drug beats placebo." The primary efficacy endpoint was percentage change in body weight at 48 weeks, reported separately for each dose cohort and for the placebo arm.
Placebo-corrected weight change was statistically significant across all active dose groups throughout the 48-week observation period. The responder analyses — the proportion of participants achieving at least 10% and at least 20% body weight reduction from baseline — showed particularly dramatic dose-dependent separation from placebo, with higher-dose cohorts approaching near-complete responder rates for the 10% threshold. These responder rates matter for research protocol design because they confirm that the efficacy signal is not being driven by a small subset of hyper-responders; it reflects a broad, consistent population-level effect.
| Cohort Group | Mean Body Weight Change at 48 Weeks | Proportion Achieving ≥10% Reduction | Proportion Achieving ≥20% Reduction |
|---|---|---|---|
| Placebo | −2.1% | ~16% | ~2% |
| Lower dose cohorts (research context) | −8.7% to −17.1% | ~52% to ~78% | ~19% to ~48% |
| Higher dose cohorts (research context) | −22.8% to −24.2% | ~91% to ~100% | ~67% to ~83% |
Secondary endpoints deserve focused attention because they distinguish the Jastreboff 2023 paper from generic weight-loss trial reports. Beyond body weight, the paper documented meaningful reductions in waist circumference, fasting glucose, triglycerides, and — critically — hepatic fat fraction measured by MRI-PDFF (proton density fat fraction). In the higher-dose cohorts, mean relative reductions in liver fat exceeded 80%. For UAE research institutions investigating NAFLD, steatohepatitis, or cardiometabolic risk models, that hepatic fat signal is arguably more scientifically interesting than the body weight headline.
Tolerability data from the phase 2 trial followed the established GLP-1 receptor agonist class profile. Nausea, vomiting, and diarrhoea were the most frequently reported adverse events, predominantly mild to moderate in severity and concentrated during the dose-escalation phase rather than the maintenance period. No unexpected safety signals emerged outside the known incretin class. This tolerability characterisation is directly relevant for research teams designing animal or ex-vivo protocols informed by human pharmacology: the dose-escalation approach used in the Jastreboff trial was explicitly designed to manage tolerability during the ramp period, and any research protocol referencing this literature should engage with that design rationale explicitly.
Retatrutide — 5mg & 10mg Research Vials, In Stock UAE
Referenced in Jastreboff 2023 NEJM and the TRIUMPH Phase 3 programme. Same-day Dubai dispatch for orders before noon GST. Cold-chain, discreet packaging. COD available across UAE.
Buy Retatrutide UAE — Same-Day Dubai Dispatch from REVIVE LAB UAEThe Jastreboff 2023 NEJM publication was, by design, a phase 2 signal-finding study. Its 338-participant population and 48-week horizon were sized to demonstrate proof-of-concept and characterise the dose-response curve — not to power a regulatory submission. The TRIUMPH phase 3 clinical programme that Eli Lilly subsequently initiated was built to supply exactly what the phase 2 paper couldn't: large-population efficacy confirmation, extended-duration safety surveillance, and cardiovascular outcomes data that regulatory agencies require before any commercial approval pathway opens.
TRIUMPH trial readouts have provided the research community with a substantially larger dataset confirming the phase 2 signals at scale. Extended-duration weight maintenance data from TRIUMPH — following participants beyond the 48-week phase 2 observation window — addresses a question that the Jastreboff 2023 paper explicitly left open: does the weight reduction plateau, continue, or regress when the titration phase ends and participants reach maintenance dosing? The TRIUMPH data gives researchers the longer arc of the pharmacological story.
Two TRIUMPH sub-studies are of particular relevance to UAE research contexts. The cardiovascular outcomes component addresses risk markers that are disproportionately prevalent in Gulf populations — a disease burden that makes cardiovascular metabolic research directly relevant to regional health priorities. The NAFLD/NASH sub-study extends the hepatic fat signal first reported in the Jastreboff 2023 paper into a larger, longer-duration observation. Research groups at Abu Dhabi institutions or Dubai universities building investigative frameworks around liver disease models have a specific reason to follow TRIUMPH readouts closely.
From a procurement intelligence perspective, the TRIUMPH data also signals trajectory. Research teams at biotech startups in Dubai Science Park, private research facilities in JBR, or university laboratories in Sharjah who establish working protocols with retatrutide now — using research-grade supply from a reliable UAE source — are building institutional familiarity with a compound that the TRIUMPH programme consistently positions as a best-in-class candidate. The research precedent established now translates to protocol expertise later.
One of the most operationally valuable elements of the Jastreboff 2023 NEJM publication — beyond the efficacy numbers themselves — is the stepwise dose-escalation architecture used across trial cohorts. The trial did not simply assign participants to a fixed dose from week one. It employed a titration-escalation approach in which doses were increased at defined intervals, explicitly designed to allow tolerability to establish before advancing to higher exposure levels. For research teams designing protocols informed by this published pharmacology, that escalation structure is a meaningful reference framework, not incidental trial logistics.
Within the studied ranges, the 2mg, 4mg, and 8mg weekly subcutaneous dose levels represent the core titration ladder documented in the phase 2 data. Each step corresponds to a distinct pharmacokinetic exposure range, and the Jastreboff 2023 paper provides stratified efficacy and tolerability data that lets researchers understand what is happening mechanistically at each level rather than treating dose simply as a dial to turn up. Research protocols that reference this literature — for animal model design, receptor binding studies, or in-vitro cellular work — should engage with these specific dose levels rather than extrapolating beyond what the published evidence supports.
| Titration Step (Research Reference) | Role in Phase 2 Escalation Design | Key Pharmacological Observable (Phase 2) |
|---|---|---|
| 2mg weekly (research context) | Initial low-exposure period; tolerability establishment | Early metabolic signal onset; GLP-1 and GIP receptor occupancy at sub-saturating levels |
| 4mg weekly (research context) | Mid-escalation; measurable efficacy range | Meaningful body weight and metabolic marker changes; hepatic fat reduction signal emerging |
| 8mg weekly (research context) | Higher-exposure maintenance range | Peak efficacy in mid-range cohorts; pronounced hepatic fat reduction; enhanced lipid parameter changes |
REVIVE LAB UAE supplies retatrutide in 5mg and 10mg lyophilised vials for research use only. These configurations are specifically practical for preparing the 2mg, 4mg, and 8mg reference concentrations when reconstituted per standard laboratory protocols. Research teams at Dubai universities or private labs in Business Bay running multi-step titration reference protocols will find the 10mg vial the more economically efficient choice for a full escalation run — it provides sufficient material for multiple preparation steps without requiring multiple vial orders. The 5mg vial suits single-step or lower-volume experimental designs. Both configurations ship with documentation noting research-use-only status.
The UAE's research infrastructure has undergone a structural transformation over the past five years that directly explains why peptide procurement — and retatrutide procurement specifically — is now a serious institutional activity rather than an occasional ad-hoc purchase. Dubai Science Park, the Mohammed Bin Rashid University of Medicine and Health Sciences cluster, Abu Dhabi's expanding biomedical research initiatives through institutions like NYU Abu Dhabi and Khalifa University, and a growing cohort of privately funded research facilities across DIFC, Business Bay, and Al Quoz have collectively created a research ecosystem with genuine purchasing power and genuine scientific ambition.
Retatrutide has become one of the most-searched peptide compounds among UAE research buyers for three converging reasons. First, the Jastreboff 2023 NEJM paper gave it mainstream scientific credibility that drove academic interest across the Gulf region — it appeared in institutional journal clubs and research planning meetings almost immediately after publication. Second, the TRIUMPH phase 3 data kept it in international scientific spotlight through 2024 and 2025, sustaining interest long past the usual novelty window of a single phase 2 paper. Third — and this is the specifically UAE dimension — the Gulf region carries a disproportionately high burden of metabolic disease, including type 2 diabetes, obesity, and non-alcoholic fatty liver disease. A GIP/GLP-1/glucagon triple agonist is not an abstract curiosity for UAE researchers; it addresses disease mechanisms that are directly, urgently relevant to the population these institutions exist to serve.
The procurement problem that UAE research teams have historically faced with peptides is not demand — it is reliable supply with appropriate logistics. Ordering retatrutide from US or European suppliers means 7-to-14-day shipping windows, exposure to UAE customs processing variability at DXB, cold-chain integrity risk across a 30-plus-hour transit, and zero local recourse when vials arrive compromised. For a researcher in the Marina or JBR running a time-sensitive protocol, a late vial is not an inconvenience; it is a data integrity failure that can invalidate weeks of experimental preparation. REVIVE LAB UAE was built specifically to close this supply gap: locally held stock, same-day Dubai dispatch, cold-chain managed from UAE warehouse to recipient door, and a WhatsApp contact channel that operates in Gulf Standard Time business hours rather than US Eastern or Central European time.
Researchers across the UAE ordering retatrutide from REVIVE LAB UAE receive lyophilised vials in two configurations: 5mg and 10mg. Both are prepared to research-grade specification, cold-chain packaged at the point of dispatch, and shipped in unmarked discreet outer packaging with no compound name, no supplier branding, and no identifying information on the external label. For research facilities operating from shared-building addresses in DIFC, Business Bay, or Palm Jumeirah where incoming package discretion is a standard operating requirement, this is a non-trivial detail that REVIVE LAB UAE has built into its default dispatch protocol rather than offering as an add-on.
Payment flexibility at REVIVE LAB UAE is broader than most international peptide suppliers targeting UAE buyers. Cash on delivery (COD) is available for Dubai addresses, which removes the upfront payment friction that research procurement departments sometimes face when attempting international wire transfers or card authorisations. Binance Pay via USDT TRC20 is accepted as a second checkout method with a 5% pre-pay discount applied automatically — a meaningful saving for research teams placing regular bulk procurement runs. All orders are confirmed via WhatsApp, providing a direct communication channel for time-sensitive procurement coordination, order tracking, and Binance Pay transaction ID confirmation.
Orders placed with REVIVE LAB UAE before 12:00 noon Gulf Standard Time (GST) on any business day are dispatched same-day within Dubai. That covers the full Dubai geography: Downtown, Business Bay, DIFC, Palm Jumeirah, JBR, Dubai Marina, Jumeirah, Al Quoz, Deira, Bur Dubai, and all other zones within the emirate. Next-day delivery covers Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, Fujairah, and Umm Al Quwain. A researcher in Abu Dhabi who identifies a retatrutide supply need on Monday morning has confirmed receipt by Tuesday — not three weeks from today.
REVIVE LAB UAE does not operate as a marketplace or drop-ship aggregator. When we say retatrutide in stock UAE, that is a literal statement about physical inventory held locally — not a US or Chinese warehouse claiming UAE delivery capability with a 10-day transit reality. Research directors at UAE institutions who have dealt with the difference between "ships to UAE" and "in stock in UAE" will understand immediately why this distinction matters for protocol continuity.
Yes. REVIVE LAB UAE dispatches retatrutide orders placed before 12:00 noon GST on the same business day within Dubai — covering all Dubai zones from Business Bay and DIFC to JBR and the Marina. Next-day delivery covers Abu Dhabi, Sharjah, and all remaining UAE emirates. All shipments travel in discreet, cold-chain-appropriate packaging with no compound name or supplier identification on the outer label. For urgent protocol supply requirements, WhatsApp confirmation ensures same-day dispatch awareness.
REVIVE LAB UAE stocks retatrutide in 5mg and 10mg lyophilised vials for research use only. The 2mg, 4mg, and 8mg titration reference doses studied across cohorts in the Jastreboff 2023 NEJM phase 2 trial can be prepared from both vial sizes using standard laboratory reconstitution and dilution protocols. For research teams running multi-step titration reference protocols modelled on the phase 2 escalation design, the 10mg vial provides the most practical quantity per order. The 5mg vial is suited for single-step or lower-volume experimental designs.
Yes. REVIVE LAB UAE offers cash on delivery (COD) for retatrutide research orders within Dubai and select UAE locations. Binance Pay via USDT TRC20 is also accepted UAE-wide as a second checkout method, with a 5% pre-pay discount applied automatically to qualifying orders. Contact REVIVE LAB UAE via WhatsApp to place your order, receive logistics details, and confirm your transaction ID for Binance Pay payments. The WhatsApp channel operates during UAE business hours in GST.
Order Retatrutide UAE — REVIVE LAB UAE
5mg & 10mg lyophilised vials. Physically in stock in UAE. Same-day Dubai dispatch before noon GST. Discreet cold-chain packaging. COD available. Binance Pay accepted with 5% discount.
Buy Retatrutide UAE — Order Now from REVIVE LAB UAE